ARCA biopharma Announces Special Dividend Linked to Proposed Merger
Estimated special dividend set at $1.59 per share
Payment of the special dividend is dependent on ARCA stockholder approval of the Proposed Merger
ARCA biopharma, Inc. (NASDAQ: ABIO) has revealed that its Board of Directors has approved a special cash dividend in relation to the previously announced merger with Oruka Therapeutics. This special dividend, estimated at $1.59 per share of ARCA’s common stock, will be distributed in cash to stockholders of record once the necessary conditions are fulfilled.
The precise calculation of the special dividend will rely on a good faith estimate of ARCA’s net cash position before the merger is finalized, which is expected to occur after obtaining stockholder approval. The dividend payment date is projected to be shortly after this approval.
The declaration of this special dividend hinges on ARCA stockholders voting in favor of the merger during the upcoming special meeting. If the merger receives approval, it is anticipated to close soon after.
If you require assistance with voting your shares or have any questions regarding the stockholder meeting, please reach out to ARCA’s proxy solicitor for help.
About ARCA biopharma
ARCA biopharma is dedicated to developing targeted therapies aimed at treating cardiovascular diseases through a precision medicine approach. Their goal is to improve patient outcomes by employing innovative drug development strategies.
About Oruka Therapeutics
Oruka Therapeutics is committed to creating novel biologics that aim to redefine treatment standards for chronic skin diseases. Their mission focuses on providing effective solutions for patients dealing with conditions such as plaque psoriasis.
Investor Communications
ARCA biopharma encourages its stakeholders to stay updated on the merger and other company developments through official communications. Investors are welcome to reach out with any questions related to shares and ongoing processes.
Frequently Asked Questions
What is the special dividend amount declared by ARCA biopharma?
The special dividend has been declared at an estimated amount of $1.59 per share of ARCA’s common stock.
What conditions must be met for the special dividend to be paid?
The payment of the special dividend depends on stockholder approval of the merger with Oruka Therapeutics.
When is the stockholder meeting scheduled?
The special stockholder meeting is set for a specific date and time, during which stockholders will cast their votes on the merger.
How can shareholders vote their shares?
Shareholders who need assistance with voting their shares can contact ARCA’s proxy solicitor for support.
What is ARCA biopharma’s primary focus?
ARCA biopharma focuses on developing genetically targeted therapies for cardiovascular diseases through innovative drug development approaches.